Review Article. Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) Safety Profile of NSAID
|
|
- Annice Davidson
- 6 years ago
- Views:
Transcription
1 Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) R. Stoilov: University Hospital St Ivan Rilski, Clinic of Rheumatology Contact: Rumen Stoilov, Clinic of Rheumatology, University Hospital St Ivan Rilski, 15 Acad. Ivan Geshov Blvd, 1431 Sofia, Key words: Nonsteroidal Anti-Inflammatory Drugs, Gastrointestinal toxicity, Cardiovascular toxicity, COX 2 inhibitors Abstract: NSAIDs are among the most frequently used medicinal products in medical practice. They are in great use for managing pain and other symptoms of inflammation, but they can also cause a number of adverse effects on gastrointestinal tract, cardiovascular or kidney and urinary systems, etc. The leading mechanism which defines their efficiency as well as their toxicity is the suppression of cyclooxigenesis. COX-1 inhibition is related with the manifestation of adverse drug reaction. COX-2 inhibitors have smaller gastrointestinal toxicity, though some researches suggest that long-term treatment with coxibs in high doses can increase the risk from cardiovascular incidents. This review article shows that the efficiency of coxibs is comparable to that of nonselective NSAIDs, though considerably more sparing to gastrointestinal tract, while some of them can increase the risk from cardiovascular incidents. Review Article The rheumatic diseases are characteristic with high frequency. Every 7 th inhabitant on the Earth has some rheumatic disorders, in every 3 rd family there is a member with a rheumatic problem. More than 200 rheumatic diseases are known. About 300 million in the world are only those suffering from arthritis and osteoporosis. In Europe their number is about 100 million. Most of these diseases are chronic. The rheumatic diseases are one of the most frequent causes for temporal working incapacity as well as permanent disability. The ageing of the population and the changes of the way of life of the contemporary people will increase the relative part of these chronic diseases such as osteoarthritis, osteoporosis, and various types of arthritis etc, which become more frequent in the late decades of people s lives (see Graph 1). The demographic prognosis show definite increase of the number of people of over 60 and over 80 years of age in the forthcoming decades. In Europe only the joint diseases constitute about 50% of all chronic diseases of people over 65 years of age (4). The chronic course of these diseases requires constant or intermittent treatment as well as periodical medical and laboratory control. This is connected with considerable financial funds for drugs, consumables, medical equipment, doctors labour etc. In Europe the economic burden for only rheumatic diseases is more that 200 billion euro a year (4). In many cases the working capacity may be preserved but the discomfort caused by them has influence on the quality of the professional activity of the sufferers and their quality of life in the leisure time. (Graph 1) Frequency of most common rheumatic diseases by age The most widely used medicines for the treatment of rheumatic diseases are the Nonsteroidal antiflammatory drugs. They combine antiflammatory, analgetic and antipyretic effect. Daily more than 30 million people all over the world use nonsteroidal antiflammatory drugs. 10% of the total population in most of the European countries take nonselective NSAID, whereas this percentage reaches 25 with the adults (14). With this kind of drugs symptomatic influence can be achieved on the joint pains, on the stiffness and the swelling as well as on the functional capacity of the loco- 15
2 motory system i.e. a considerable clinical improvement of the sick people. In clinical application of NSAID it is necessary to observe the following principles: adequate dosage; sufficient duration of the course of treatment; taking into consideration the individual sensitivity to NSAID; correct distribution of the prescribed dose in the twenty-four-hour period; usage of alternative forms of application (rectal, parenteral, percutanic) etc. Regardless of the fact that NSAID are extremely useful for supressing the inflammation and pain, their usage is often accompanied by adverse drug reactions. In the recent years, more and more attention is paid to the correlation benefit/risk in the clinical application of NSAID. Particular attention is worth paying to gastrointestinal adverse events (1), and recently the cardiovascular, too (8). According to the data of the Spanish system of Pharmacovigilance (SSPV) for the period , reports of adverse drug reactions were made and 8.8% out of them were caused by NSAID, thus taking the second place after the antibiotics (15.1%). The most frequently quoted NSAID are: Diclofenac (364 reports), Piroxicam (282), Indometacin (197), Naproxen (155) and Ketoprofen (137). The nonselective NSAID exert their effects by blocking, approximately to the same extent, the two isoenzymes of cyclooxygenase - COX-1 and COX-2. The suppression of the inducible COX-2 is connected with the therapeutic effects of NSAID antiflammatory, analgetic and antipyretic. The inhibition of the constitutive COX-1 which supports the homeostasis leads to adverse drug reactions from the gastro-intestinal tract, the kidneys and the cardio-vascular system.(fig. 1) The basic factors, associated with the higher risk of gastro-intestinal adverse drug reactions are: - high dose or combination of NSAID; - age over 65; - anamnesis data of the ulcer in the past; - continuous usage of NSAID; - simultaneous application of other drugs (anticoagulants, glucocorticosteroid and others); - serious concomitant illnesses; - others: presence of infection with Helicobacter Pylori, smoking, alcohol abuse and others; We must particularly be vigilant at the presence of one or several of the above factors. People using NSAID have three times higher relative risk of development of serious gastro-intestinal adverse drug reactions and two times higher relative risk of bleeding compared to those who do not use NSAID. Patients who are treated with NSAID at an older age are exposed to three times higher risk of developing gastro-intestinal complications compared to those who use NSAID at an earlier age. The serious gastro-intestinal complications due to the usage of NSAID in a number of cases can have a lethal issue. Graph 2 shows that the mortality cause due to usage of NSAID in the USA for a year is juxtaposable to that of the sufferers from AIDS. (Graph 2) The adverse effects of NSAID on the GIT are a significant cause for morbidity and mortality (11). About 60% of the patients on chronic treatment with NSAID have dyspeptic complaints: abdominal pain, sickness, vomiting, burning behind the sternum; whereas 15 30% have gastroduodenal ulcers proven by endoscopy. Most clinically significant ADR, connected with the usage of NSAID, are ulcer complications perforation, obstruction or bleeding (POB). The clinical studies show that about 1.5% of the patients with RA and OA, treated with NSAID have POB (1, 13, 14). (Fig. 2). The NSAID suppress the synthesis of the cytoprotective prostaglandines, reduce the mucous and bicarbonate secretion in the stomach, injure the surface phospholipids layer, reduce the blood circulation in the mucous membranes, and increase the acid secretion. All this upsets the balance between the protective and aggressive factors in the stomach and the duodenum 16
3 Conventional NSAIDs mechanism of action ARACHIDONIC ACID Conventional NSAIDs Prostaglandins Thromboxane Prostaglandins Gastrointestinal Toxicity Malfunction of plateles Inflammation, pain, fever Figure 1. Nonselective NSAID mechanism of action Figure 2 Adverse NSAID effects on gastric mucous membrane. 17
4 In Great Britain, about 20% of the emergency cases with complication of the upper parts of the gastro-intestinal tract were due to nonselective NSAID in only one year (about people). Seventy one percent of those using nonselective NSAID were with injured small intestines which was determined by capsule endoscopy. Only 10% of the people, who do not use this type of medicinal products, have similar injuries (7). The treatment of serious adverse drug events by GIT is connected with considerable economic losses. The total price of the treatment of one patient is from US$1800 in Switzerland to US$6500 in the Netherlands (3). (Graph 3) Graph 2. Mortality caused by gastrointestinal complications related to NSAIDs in comparison to other diseases in the USA 18
5 COX-2 conception gave rise to real hopes for optimisation of the balance between the therapeutic effectiveness and the adverse drug reactions of NSAID, i.e. between the benefit and the risk. This conception revealed the possibilities to create new generation of NSAID, called selective inhibitors of cyclooxigenase-2 (6). Today we have considerable experience in their application. The mechanism of the effect of the selective COX-2 inhibitors is presented in Figure 3. They block the inducible COX-2 and keep the constitutive COX-1. (Fig. 3) Graph 3. Direct costs associated with serious gastrointestinal adverse events (Chevat, C. et al Pharmacoeconomics, , /Suppl.1/, 17-32). 19
6 Molecular basis of COX-2 inhibition Active place Active place Side pocket Figure 3. Mechanism of action of selective COX-2 inhibitors A number of studies showed, that the selective COX-2 inhibitors have anaesthetizing and antiflammatory effect, juxtaposed to that of the non-selective NSAID, but to a considerably larger extent protect the gastroduodenal mucous membrane (10, 13, 15, 16). Recently it has been found out that some representatives of COX-2 inhibitors with continuous usage lead to cardiovascular complications. This gave rise to prerequisites to shake the positive attitude to highly selective COX-2 inhibitors, called coxibis. 20
7 Prothrombotic hypothesis Vascular prostacyclin Platelet TXA2 Partial block COX-2 Specific inhibitors Conventional NSAIDs No block of TXA2 Vasodilation and endothelial function Platelet aggregation and vasoconstriction Misbalance can lead to prothrombotic state and can increase the cardiovascular risk Figure 4. Prothrombotic hypothesis It is admitted that COX-2 inhibition leads to increase of the potential risk of the thromboembolic cardiovascular events, as it was found out in the study VIGOR (9). The presumptive mechanism for this is connected with the suppression of the synthesis of the vascular prostacyclin (PgI2), without suppressing the synthesis of thromboxane A2 (TXA2) of the thrombocytes. COX-2 inhibitors do not influence the thrombocyte aggregation (12, 18). Fig. 4 presents the prothrombotic hypothesis (Fig. 4). 21
8 Figure 5. First and second generation coxibs chemical formulae of structure We have to underline that the patients participating in the study VIGOR are treated with Vioxx (rofecoxib), 50 mg/daily, in the course of one year (2). For the time being, there are no data that other COX-2 selective inhibitors bring to a higher risk of cardiovascular complications (9). Having in mind that COX-2 selective inhibitors are different chemical compounds, it seems more likely that the matter is about specific effect of a drug and not a class specific effect. Fig. 5 presents the chemical structural formulae of different coxibs in two basic groups sulfonamides and sulfonyls (Fig. 5). 22
9 Graph 4. Risk from acute MI related with COX-2 selective inhibitors and nonselective NSAIDs (~1.4 million patients) At present, we can consider that the clinical data causing the withdrawal of Vioxx (rofecoxib) are specifically connected with it and they should not be referred implicitly to the rest of the COX-2 selective inhibitors. With about 1.4 million patients in the USA, who use COX-2 selective and non-selective NSAID, the risk of acute myocardial infarction has been studied. It has been found out that with patients using celecoxib, the risk of acute myocardial infarction is commensurable with the control group, in contrast to those treated with rofecoxib, 50 mg/daily, and some other nonselective NSAID (8, 17). Graph 4 presents the data of Nested Case-Control Study published in Lancet 2005 (8) (Graph 4) The American Agency of Food and Drugs (FDA) recommends to the pharmaceutical companies to revise the medical indications of nonselective NSAID, as well as of COX-2 inhibitors. These should include special warning for higher risk of cardiovascular adverse events and life threatening gastro-intestinal hemorrhages (5). In the USA and Canada COX-2 inhibitors are counter-indicative in coronary-arterial bypass surgery and perioperative application in cardiac-surgery. In Europe (EMEA recommendation) COX-2 selective inhibitors and nonselective NSAID have different medical information. The contraindications about the application of COX-2 selective inhibitors are: cardiac insufficiency II-IV class by NYHA, determined ischemic heart disease peripheral artery diseases, cerebral artery diseases, uncontrolled hypertonia (only for Arcoxia [etoricoxib]) 23
10 REFERENCES 1. Armstrong CP, Blower AL. Non-Steroidal Anti-Inflammatory Drugs And Life Threatening Complications Of Peptic Ulceration. Gut. 1987; 28: Bombardier C. et al for the VIGOR Study Group. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib And Naproxen In Patients With Rheumatoid Arthritis. N Engl J Med. 2000; 343: Chevat C. et al. Healthcare Resourse Utilisation And Costs Of Treating NSAID-Associated Gastrointestinal Toxicity. A Multinational Perspective. Pharmacoeconomics, 2002; 19 /Suppl.1/: European Science Foundation, 26; 2006: FDA News, April Goldstein J.L. et al. Reduced Risk of Upper Gastrointestinal Ulcers With Celexocib: a Novel COX 2 Inhibitors. Am J Gastroenterol. 2000; 95: Graham D.J.et al Clin. Visible Small-Intestinal Injury in Chronic NSAID Users. Gastroenterol. Hepatol. 2005; 3: Graham D.J. et al. Risk of Acute Myocardial Infarction and Sudden Cardiac Death in Patients Treated with Cyclo-Oxygenase 2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs: Nested Case-Control Study. Lancet 2005; 365: Mukherjee D. et al. Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors. JAMA.2001; 286: Mckenna F. et al. Celecoxib Versus Diclofenac in the Management of Osteoarthritis of the Knee. Scand J Rheumatol. 2001; 30: National Center for Health Statistics, Ray W. et al. Weighing the Risks and Benefits of Coxibs, NSAIDs and Antiplatelet Therapy: Where the Data Lead. Lancet. 2002; 360: Singh G. et al. Gastrointestinal Tract Complications of Nonsteroidal Anti-Inflammatory Drug Treatment in Rheumatoid Arthritis. A Prospective Observational Cohort Study. Arch Intern Med. 1996; 156: Singh G., Triadafilopoulos. Epidemiology of NSAID Induced Gastrointestinal Complications.J Rheumatol. 1999; 26(suppl 56): Singh G., et al for the SUCCESS-I Investigators. Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study. Am J Med. 2006; 119: Silverstein F.F., et al. Gastrointestinal Toxicity with Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis. JAMA. 2000; 284: White W.B. et al. Comparison of Thromboembolic Events in Patients Treated with Celecoxib, a Cyclooxygenase 2 Specific Inhibitor, Versus Ibuprofen or Diclofenac. Am J Cardiol. 2002; 89: Wilner K.D. et al. Celecoxib Does not Affect the Antiplatelet Activity of Aspirin in Healthy Volunteers. J Clin Pharmacol. 2002; 42: Abbreviations: GIT gastrointestinal tract CVS cardiovascular system NSAID nonsteroid anatiflammatory drugs ADR adverse drug reactions COX-1 - cyclooxygenaseisoenzyme 1 COX-2 - cyclooxygenaseisoenzyme 2 POB - perforation, obstruction, bleeding RA rheumatoid arthritis OA - osteoartrosis AMI acute myocardial infarction 24
NSAIDs: Side Effects and Guidelines
NSAIDs: Side Effects and James J Hale FY1 Department of Anaesthetics Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse group of drugs that have analgesic, antipyretic and anti-inflammatory
More informationGastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationCARDIOVASCULAR RISK and NSAIDs
CARDIOVASCULAR RISK and NSAIDs Dr. Syed Ghulam Mogni Mowla Assistant Professor of Medicine Shaheed Suhrawardy Medical College, Dhaka INTRODUCTION NSAIDs are most commonly prescribed drugs Recent evidence
More informationCharacteristics of selective and non-selective NSAID use in Scotland
Characteristics of selective and non-selective NSAID use in Scotland Alford KMG 1, Simpson C 1, Williams D 2 1 Department of General Practice & Primary Care, The University of Aberdeen. 2 Department of
More informationVimovo (delayed-release enteric-coated naproxen with esomeprazole)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.17.01 Subject: Vimovo Page: 1 of 5 Last Review Date: September 18, 2015 Vimovo Description Vimovo (delayed-release
More informationPresentation Outline. Introduction to Biomedical Research Designs. EBM: A Practical Definition. Grade the Evidence (Example McMaster Grading System)
Presentation Outline Introduction to Biomedical Research Designs Sean D. Sullivan, R.Ph., PhD Professor of Pharmacy, Public Health and Medicine University of Washington Why a course in Biomedical Research
More informationNSAID Use in Post- Myocardial Infarction Patients. Leah Jackson, BScPhm Pharmacy Resident Cardiology Rotation February 28, 2007
NSAID Use in Post- Myocardial Infarction Patients Leah Jackson, BScPhm Pharmacy Resident Cardiology Rotation February 28, 2007 Objectives By the end of the presentation, the audience will be able to use
More informationNSAIDs Overview. Souraya Domiati, Pharm D, MS
NSAIDs Overview Souraya Domiati, Pharm D, MS Case A 32 years old shows up into your pharmacy asking for an NSAID for his ankle pain He smokes1 pack/day His BP is 125/75mmHg His BMI is 35kg/m2 His is on
More informationNSAID Use in Post- Myocardial Infarction Patients
NSAID Use in Post- Myocardial Infarction Patients Leah Jackson, BScPhm Pharmacy Resident Cardiology Rotation February 28, 2007 Objectives By the end of the presentation, the audience will be able to use
More informationNON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK. Advances in Cardiac Arrhythmias and Great Innovations in Cardiology
NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK Advances in Cardiac Arrhythmias and Great Innovations in Cardiology Torino, October 15, 2016 Giuseppe Di Pasquale Direttore Dipartimento Medico
More informationRimoxen. Rimoxen! "The Gastro and Cardio friendly anti-inflammatory ingredient"
Rimoxen A Botanical Anti-Inflammatory COX-2 Selective Ingredient Question: How doses Rimoxen compare to the prescription COX-2 inhibitors (Vioxx and Celebrex) and the OTC NSAID pain relievers such as aspirin
More informationAli Jaber, Ph.D. MS in Pharmacy MS in Pharmaceutical Chemistry
Nonsteroidal antiinflammatory drugs (NSAID) Ali Jaber, Ph.D. MS in Pharmacy MS in Pharmaceutical Chemistry The inflammatory response occurs in vascularised tissues in response to injury. It is part of
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationDisclosure. Learning Objectives 1/17/2018. Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with NSAID Use
Disclosure Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with Liz Van Dril, PharmD, BCPS PGY2 Ambulatory Care Resident January 17 th, 2018 Dr. Liz Van Dril has no actual or potential
More informationEffective management of gastrointestinal PROCEEDINGS EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS *
EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS * David A. Peura, MD, FACP, FACG ABSTRACT *This article is based on a presentation given by Dr Peura at the PRI-MED
More informationcyclooxygenase-2 (COX-2)-selective
Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs Cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drugs (NSAIDs) have often been used in recent years
More informationAbwägung zwischen Schaden und Nutzen medizinischer Interventionen
Abwägung zwischen Schaden und Nutzen medizinischer Interventionen Peter Jüni Institut für Sozial and Präventivmedizin, Universität Bern CTU Bern, Inselspital Bern Outline Wall Street, New York, Sept 30,
More informationIroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low
More informationNon-steroidal anti-inflammatory drugs and gastrointestinal damage problems and solutions
82 University of Glasgow and Department of Gastroenterology, Royal Infirmary, Glasgow Correspondence to: Professor R I Russell, 28 Ralston Road, Bearsden, Glasgow G61 3BA rirla@aol.com Submitted 26 October
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationManaging Musculoskeletal Pain and Injury
Managing Musculoskeletal Pain and Injury New & Old Drugs: Best Choices MAY 5, 2017 WILLIAM KNOPP, MD Dr. Knopp indicated no potential conflict of interest to this presentation. He does not intend to discuss
More informationNSAIDs: The Truth About Cardiovascular Risk
NSAIDs: The Truth About Cardiovascular Risk Adam Grunbaum DO FACOI FACR American College of Osteopathic Internists Annual Convention and Scientific Sessions October 3 rd 2015 Disclosures none 2 Objectives
More informationA Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury
A Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury A. Mark Fendrick, MD Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed often in the U.S., particularly
More informationEtoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets 23.5.2016, Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Etoricoxib STADA 30 mg film-coated
More informationDrug Use Criteria: Cyclooxygenase-2 Inhibitors
Texas Vendor Program Use Criteria: Cyclooxygenase-2 Inhibitors Publication History Developed January 2002. Revised May 2016; October 2014; February 2013; December 2012; March 2011; January 2011; October
More informationFigure 13-1: Antiplatelet Action of Aspirin (Modified After Taneja et.al 2004) ASPIRIN RESISTANCE
CHAPTER 13 ASPIRIN Action Aspirin Resistance Aspirin Dose Therapeutic Efficacy - Secondary prevention - Acute coronary syndromes - Primary prevention Limitations and Side Effects Aspirin Aspirin should
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Celebrex) Reference Number: CP.CPA.239 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationThink Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks
NEWS AND PERSPECTIVES Think Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks Jyh-Ming Liou, 1,2 Ming-Shiang Wu, 1 * Jaw-Town Lin 1,3 Nonsteroidal
More informationNon-Steroidal Anti- Inflammatory Drugs. ATPE 410 Chapter 6
Non-Steroidal Anti- Inflammatory Drugs ATPE 410 Chapter 6 Inflammatory Process A normal, beneficial process that begins immediately after injury to facilitate repair and return the tissue to normal function
More informationAccounting for cardiovascular risk when prescribing NSAIDs
MEDICINES OPTIMISATION Accounting for cardiovascular risk when prescribing NSAIDs DAVID LAIGHT It is now recognised that oral NSAIDs can increase the risk of cardiovascular events, including myocardial
More informationEffective Health Care Program
Comparative Effectiveness Review Number 38 Effective Health Care Program Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review Executive Summary Background Osteoarthritis
More informationPain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia
Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans. 1 Pain
More informationWhat Is Peptic Ulcer Disease?
What Is Peptic Ulcer Disease? Peptic ulcer disease is when painful sores form in the lining of the stomach, duodenum (start of the small intestine) or bowels. An ulcer can cause belly pain and, in some
More informationThis document has not been circulated to either the industry or Consultants within the Suffolk system.
New Medicine Report Document Status COX II Inhibitors In Acute Analgesia For Suffolk Drug & Therapeutics Committee Date of Last Revision 15 th February 2002 Reviewer s Comments There seems to be a growing
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More informationTECHNOLOGY OVERVIEW. Issue 6 February Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis
TECHNOLOGY OVERVIEW Issue 6 February 2002 Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis Publications can be requested from: CCOHTA 110-955 Green
More informationAVERTING RISKS ASSOCIATED WITH UTILISING SMALL ANIMAL NSAIDS
Vet Times The website for the veterinary profession https://www.vettimes.co.uk AVERTING RISKS ASSOCIATED WITH UTILISING SMALL ANIMAL NSAIDS Author : Catherine F Le Bars Categories : Vets Date : April 6,
More informationAsprin Bryce Gates Richard hammond Agustin chavez
Asprin Bryce Gates Richard hammond Agustin chavez Who discovered asprins? The discovery of aspirin is customarily said to have resulted from Felix Hoffmann's rheumatic father encouraging his son to produce
More informationPain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia
Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans 2. Pain
More informationASPIRIN AND VASCULAR DISEASE
ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationReview Article. NSAID Gastropathy: An Update on Prevention. Introduction. Risk Factors. Kam-Chuen Lai
Review Article NSAID Gastropathy: An Update on Prevention Kam-Chuen Lai Abstract: Keywords: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs) are common. Upper gastrointestinal complications
More informationBalanced Analgesia With NSAIDS and Coxibs. Raymond S. Sinatra MD, Ph.D
Balanced Analgesia With NSAIDS and Coxibs Raymond S. Sinatra MD, Ph.D Prostaglandins and Pain The primary noxious mediator released from damaged tissue is prostaglandin (PG) PG is responsible for nociceptor
More informationRisk Management Plan Etoricoxib film-coated tablets
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis (OA): OA is a condition in which the cartilage of the joints is broken down. This causes stiffness, pain and leads
More informationETIOPATHOGENICAL ASPECTS OF NONSTEROIDAL ANTI- INFLAMMATORY DRUGS IN ELDERLY Mihaela Bursova¹, Gabriela Lilios², Maria Suta³, Gh.
ETIOPATHOGENICAL ASPECTS OF NONSTEROIDAL ANTI- INFLAMMATORY DRUGS IN ELDERLY Mihaela Bursova¹, Gabriela Lilios², Maria Suta³, Gh. Taralunga² 1.CLINICAL EMERGENCY COUNTY HOSPITAL CONSTANŢA, GERIATRICS DEPARTAMENT
More informationNONSTEROIDAL ANTI- INFLAMMATORY DRUGS
NONSTEROIDAL ANTI- INFLAMMATORY DRUGS MRS. M.M. HAS A 3 YR. HX OF PROGRESSIVE RIGHT HIP PAIN. THE PAIN INCREASES WITH WEIGHT BEARING ACTIVITY. PT. HAS BEEN ON ACETAMINOPHEN WITHOUT RELIEF. PERTINENT LABS
More informationModelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M
Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Prescription of Nonsteroidal Anti-inflammatory Drugs and Co-prescribed Drugs for Mucosal Protection: Analysis of the Present Status Based on Questionnaires Obtained from Orthopedists in
More informationPRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation
PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY This audit has been designed to ensure that patients
More informationNon-steroidal anti-inflammatory drugs: who should receive prophylaxis?
Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 59 64. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? C. J. HAWKEY Wolfson Digestive Diseases Centre, Institute of Clinical Research,
More informationPapers. Abstract. Introduction. Methods. Jonathan J Deeks, Lesley A Smith, Matthew D Bradley
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Jonathan J Deeks, Lesley
More informationPHARMACOTHERAPEUTIC ANALYSIS OF NON- STEROIDAL ANTI-INFLAMMATORY DRUGS PRESCRIBED AT RHEUMATOLOGY / ORTHOPEDIC CLINICS. Waleed M.
J. Al Azhar University-Gaza 2003,Vol. 6, 2 P.47-56 PHARMACOTHERAPEUTIC ANALYSIS OF NON- STEROIDAL ANTI-INFLAMMATORY DRUGS PRESCRIBED AT RHEUMATOLOGY / ORTHOPEDIC CLINICS. Waleed M. Sweileh An-Najah National
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationEICOSANOID METABOLISM
1 EICOSANOID METABOLISM EICOSANOIDS C20 polyunsaturated fatty acids e.g. Arachidonic acid Eicosanoids physiologically, pathologically and pharmacologically active compounds PG Prostaglandins TX - Thromboxanes
More informationMitigating GI Risks Associated with the Use of NSAIDs
bs_bs_banner Pain Medicine 2013; 14: S18 S22 Wiley Periodicals, Inc. Mitigating GI Risks Associated with the Use of NSAIDs Mahnaz Momeni, MD,* and James D. Katz, MD Departments of *Rheumatology, Medicine,
More informationTIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain
TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,
More informationCyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs Carlo Patrono, 1 Paola Patrignani, 1 and Luis A. García Rodríguez 2 1 Department
More informationAlgorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs)
Algorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs) Page 3 Publisher Conseil du médicament www.cdm.gouv.qc.ca Coordination Anne Fortin, Pharmacist Development Conseil du médicament Fédération
More information- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e
-1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,
More informationMUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed
MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationIndex. B Biotransformation, 112 Blood pressure, 72, 75 77
Index A Acute gout, treatment, 41 Adenomatous polyposis coli (APC), 224 Adenomatous polyp prevention on Vioxx (APPROVe), 250 Ankylosing spondylitis (AS), 40 41 Antiplatelet therapy, 138 Antithrombotic
More informationCOX-2 inhibitors: A cautionary tale. October 2, 2006
COX-2 inhibitors: A cautionary tale October 2, 2006 Molecular interventions in human disease... An approach as old as human civilization. With whom the herbs have come together Like kingly chiefs unto
More informationNonsteroidal Anti inflammatory Drugs (NSAIDs)
Nonsteroidal Anti inflammatory Drugs (NSAIDs) PHL-358-PHARMACOLOGY AND THERAPEUTICS-I Mr.D.Raju,M.phar, Lecturer Analgesic Antipyretic Anti inflammatory (at higher doses) Common Pharmacological Effects
More informationPain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain
Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers
More informationEtoricoxib. Database Entry. DaMocles Group V: Steffen Haller, Rene Häußler, Jonas Kaffenberger, Julian Kirsch
Etoricoxib Database Entry DaMocles Group V: Steffen Haller, Rene Häußler, Jonas Kaffenberger, Julian Kirsch 1 Table of contents 1. General information... 3 2. Value of coxibs... 4 3. Structure... 5 4.
More informationTABLE OF CONTENTS. COX-2 Inhibitors Cardiovascular and Gastrointestinal Safety
TABLE OF CONTENTS COX-2 Inhibitors - Cardiovascular and Gastrointestinal Safety 1-2 Oral Erythromycin and Risk of Sudden Cardiac Death 2-3 Common Drug Interactions between Herbal and Prescription Medications
More informationAnti-inflammatory drugs
Anti-inflammatory drugs 1 Inflammatory process 1. stimulus (cut) 2. Initial local vasoconstriction( blood loss) 3. vasodilation, local immune/inflammatory reaction (heat, redness) 4. swelling and pain
More informationIMMEDIATE DICLOFENAC NEW CONTRAINDICATIONS AND WARNINGS AFTER A EUROPE-WIDE REVIEW OF CARDIOVASCULAR SAFETY
Finance, EHealth and Pharmaceuticals Directorate Pharmacy and Medicines Division T: 0131-244 2528 E: irene.fazakerley@scotland.gsi.gov.uk 1. Medical Directors 2. Directors of Public Health 3. Directors
More informationMonth/Year of Review: January 2012 Date of Last Review: February 2007
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:
More informationManagement of nonsteroidal anti-inflammatory drug
BYRON CRYER, MD ABSTRACT OBJECTIVE: To describe risk factors and review appropriate management strategies for patients who experience nonsteroidal anti-inflammatory drug (NSAID)-related gastrointestinal
More informationChildren Enteric coated tablet : 1-3 mg/kg per day in divided doses.
Ultrafen Tablet/SR Tablet/Suppository/Gel Description Ultrafen is a preparation of Diclofenac is a non-steroidal antiinflammatory agent with marked analgesic, anti-inflammatory and antipyretic properties.
More informationIn 1971, Sir John Vane proposed that nonsteroidal
Non-steroidal antiinflammatory drugs: facts and fallacies This article serves to review NSAIDs, their mechanism of action and adverse effects, as well as to establish the therapeutic position of the new-generation
More informationDrug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Final Update 4 Report November 2010 The purpose of the is to summarize key information contained in the Drug Effectiveness Review Project
More informationDurlaza. Durlaza (aspirin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.13 Subject: Durlaza Page: 1 of 4 Last Review Date: September 15, 2016 Durlaza Description Durlaza
More informationDyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac
Aliment Pharmacol Ther 2002; 16: 819 827. Dyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac J. L. GOLDSTEIN*, G. M. EISEN, T. A. BURKEà, B. M. PEÑA, J. LEFKOWITH
More informationHelpline No:
ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 DRUGS AND ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our
More informationHypertension in Systemic Diseases
Hypertension in Systemic Diseases Prof. Andrzej Więcek FRCP (Edin.), FERA Department of Nephrology, Transplantation and Internal Medicine Medical University of Silesia, Katowice, Poland Hypertension in
More informationNSAID Regional Audit Group Presentation. Audit Group: Dr Richard Latten, Ruth Clark, Dr Sarah Fradsham, Dr Seamus Coyle, Claire Johnston
NSAID Regional Audit Group Presentation Audit Group: Dr Richard Latten, Ruth Clark, Dr Sarah Fradsham, Dr Seamus Coyle, Claire Johnston Thank you from the audit group for all who participated in the data
More informationCelecoxib: the need to know for safe prescribing
medicine indications pain management rheumatology Celecoxib: the need to know for safe prescribing Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor that has been fully subsidised without restriction,
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More information(i) Is there a registered protocol for this IPD meta-analysis? Please clarify.
Reviewer: 4 Additional Questions: Please enter your name: Stefanos Bonovas Job Title: Researcher Institution: Humanitas Clinical and Research Institute, Milan, Italy Comments: The authors report the results
More informationCan We Trust the Clinical Trials? Björn Beermann, MD,PhD, Professor Medical Products Agency Uppsala Sweden
Can We Trust the Clinical Trials? Björn Beermann, MD,PhD, Professor Medical Products Agency Uppsala Sweden Can We Trust the Clinical Trials? Yes, if they are performed according to GCP etc BUT But do we
More informationAcetaminophen and NSAIDS. James Moriarity MD University of Notre Dame
Acetaminophen and NSAIDS James Moriarity MD University of Notre Dame Lecture Goals Understand the indications for acetaminophen and NSAID use in musculoskeletal medicine Understand the role of Eicosanoids
More information& Cardiovascular Risk
Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti Ospitalieri di Cremona NSAIDs NSAIDsare widely used since they are indicated
More informationPrevalence of gastroduodenal lesions in chronic nonsteroidal anti-inflammatory drug users presenting with dyspepsia at the Kenyatta National Hospital
Research Article Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya Corresponding author: Dr. G O Oyoo. Email: geomondi@hotmail. com Prevalence of gastroduodenal lesions in
More informationDrug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs () UPDATED FINAL REPORT #1 September 2003 Mark Helfand, MD, MPH Oregon Evidence-based Practice Center Oregon
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Celebrex) Reference Number: CP.PMN.122 Effective Date: 01.01.07 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationEtodolac versus meloxicam
Etodolac versus meloxicam The Borg System is 100 % Etodolac versus meloxicam Etodolac versus meloxicam -- 722 75051 1991 Wainwright Not Specific Enough. The store also now says majority of Irish willing
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 January 2012 ARCOXIA 30 mg, film-coated tablet B/28 (CIP code: 387 980-8) B/98 (CIP code: 573 530-9) ARCOXIA 60
More informationIroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults
Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed
More informationDiscrepancy Among Observational Studies: Example of Naproxen- Associated Adverse Events
The Open Rheumatology Journal, 2009, 3, 1-8 1 Open Access Discrepancy Among Observational Studies: Example of Naproxen- Associated Adverse Events Elham Rahme *,1,2, Jean-Philippe Lafrance 3, Hacene Nedjar
More informationCounselling on non-steroidal anti-inflammatory drugs By Megan Deldot and Associate Professor Lisa Nissen
Counselling on non-steroidal anti-inflammatory drugs By Megan Deldot and Associate Professor Lisa Nissen A 72-year-old man, Mr BK, presents to the pharmacy requesting Voltaren Rapid for his bad arthritis.
More informationSESSION 5 2:20 3:35 PM
SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationNOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg.
NOTOPAIN CAPLETS Diclofenac Sodium + Paracetamol Composition Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg Pharmacology Phamacodynamics Diclofenac relieves pain and inflammation
More informationSPECIAL REPORT. Aspirin and Risk of Gastroduodenal Complications
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:725 735 SPECIAL REPORT Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions
More informationSummary of the risk management plan (RMP) for Clopidogrel/Acetylsalicylic acid Teva (clopidogrel / acetylsalicylic acid)
EMA/411850/2014 London, 28 July 2014 Summary of the risk management plan (RMP) for (clopidogrel / acetylsalicylic acid) This is a summary of the risk management plan (RMP) for, which details the measures
More information-Mohammad Ashraf. -Anas Raed. -Alia Shatnawi. 1 P a g e
-1 -Mohammad Ashraf -Anas Raed -Alia Shatnawi 1 P a g e Dr. Alia started the lecture by talking about subjects we are going to cover through this course; you can refer to the record if you are interested.
More informationClinical Investigations and Reports. Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Clinical Investigations and Reports Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib Marvin A. Konstam, MD; Matthew R. Weir, MD; Alise Reicin, MD; Deborah Shapiro, DrPh; Rhoda
More information